OSSIO Rolls Out OSSIOfiber Suture Anchors in U.S.

OSSIO began the U.S. launch and first commercial use of OSSIOfiber suture anchors, expanding its growing portfolio of bio-integrative implants for orthopedic surgery.
 
Gregory Berlet, M.D., founding partner at Orthopedic Foot and Ankle Center in Columbus, Ohio, recently became the first surgeon to use the new implant in clinical practice.
 
“The new OSSIOfiber Suture Anchors provide amazing strength and biology that I trust to be predictable and safe for my patients,” Dr. Berlet, chief medical officer of OSSIO, told the press. “Utilizing OSSIO’s trusted bio-integrative material, these anchors allow me to maintain my preferred technique for soft tissue fixation procedures while improving my results. This is another big step for OSSIOfiber in becoming a new material standard in orthopedic fixation.”
 
The suture anchors were cleared by the FDA this past March for soft tissue fixation to bone in the shoulder, foot/ankle, hand/wrist, and elbow in a variety of procedures. The implants use the company’s proprietary OSSIOfiber intelligent bone regeneration technology, which leaves nothing permanent behind.
 
The anchor’s DURAlink coupling tech increases stability and prevents suture slippage by connecting the eyelet to the anchor for a single stable unit. OSSIO is initially launching the 4.75 mm system for foot and ankle, followed by entry into the sports/shoulder market later this year.
 
“The OSSIOfiber 4.75 Suture Anchor represents a substantive breakthrough in soft-tissue-to-bone fixation,” said Frank Petrigliano, M.D., chief of the University of Southern California Epstein Family Center for Sports Medicine in Los Angeles. “The implants can be utilized for a broad array of sports medicine procedures, and demonstrate strong, predictable bio-integration. This technology provides a biocompatible option that achieves excellent fixation without concern for implant fracture or incomplete integration into host bone. I look forward to using the OSSIOfiber 4.75 suture anchor for my sports and shoulder cases.”
 
OSSIO CEO Brian Verrier added: “Expanding our commercialized portfolio of OSSIOfiber implants, as well as patient access to additional bio-integrative solutions, is mission critical for the company’s continued success, and the launch of our suture anchors mark a significant milestone in that effort. Sports and extremity surgeons have been asking for non-permanent suture anchors that deliver improved strength and pull-out resistance, while providing safe, predictable bio-integration. OSSIOfiber Suture Anchors have shown strength that is unrivaled and safety that is unmatched in the market, as demonstrated by our bench testing and 30 month in-life studies compared to currently marketed bio-composite anchor controls.”
 
“Additionally,” Verrier said, “our products offer enhanced ease of use due to the incredible insertion strength of our continuous mineral fiber-based platform. We are excited to offer our customers a suture anchor that provides confidence during the healing process while avoiding many of the late issues sometimes seen in traditional suture anchors.”